Structure-Based Drug Design of 2-Amino-[1,1'-biphenyl]-3-carboxamide Derivatives as Selective PKMYT1 Inhibitors for the Treatment of -Amplified Breast Cancer.

J Med Chem

State Key Laboratory of Bioactive Molecules and Druggability Assessment, International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Discovery of Chinese Ministry of Education, Guangzhou City Key Laboratory of Precision Chemical Drug Development, School of Pharmacy, Jinan University, #855 Xingye Avenue, Guangzhou 510632, China.

Published: September 2024

amplification occurs in breast cancer and currently lacks effective therapies. PKMYT1 as a synthetic lethal target for amplification holds promise for the treatment of -amplified breast cancer. Herein, we discover a series of 2-amino-[1,1'-biphenyl]-3-carboxamide derivatives as potent and selective PKMYT1 inhibitors using structure-based drug design. The representative compound exhibited excellent potency against PKMYT1, while sparing WEE1. It also suppressed proliferation of the -amplified HCC1569 breast cancer cell line and showed synergistic cytotoxicity in combination with gemcitabine. PKMYT1 X-ray cocrystallography confirmed that introduction of key binding interactions between the inhibitors and residues Asp251 and Tyr121 of PKMYT1 greatly enhanced the potency and selectivity of the compounds.

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.jmedchem.4c01458DOI Listing

Publication Analysis

Top Keywords

breast cancer
16
structure-based drug
8
drug design
8
2-amino-[11'-biphenyl]-3-carboxamide derivatives
8
selective pkmyt1
8
pkmyt1 inhibitors
8
treatment -amplified
8
-amplified breast
8
pkmyt1
6
design 2-amino-[11'-biphenyl]-3-carboxamide
4

Similar Publications

In this paper, the pH-sensitive targeting functional material NGR-poly(2-ethyl-2-oxazoline)-cholesteryl methyl carbonate (NGR-PEtOz-CHMC, NPC) modified quercetin (QUE) liposomes (NPC-QUE-L) was constructed. The structure of NPC was confirmed by infrared spectroscopy (IR) and nuclear magnetic resonance hydrogen spectrum (H-NMR). Pharmacokinetic results showed that the accumulation of QUE in plasma of the NPC-QUE-L group was 1.

View Article and Find Full Text PDF

Aim: Dynamic cancer control is a current health system priority, yet methods for achieving it are lacking. This study aims to review the application of system dynamics modeling (SDM) on cancer control and evaluate the research quality.

Methods: Articles were searched in PubMed, Web of Science, and Scopus from the inception of the study to November 15th, 2023.

View Article and Find Full Text PDF

Detection of biomarkers of breast cancer incurs additional costs and tissue burden. We propose a deep learning-based algorithm (BBMIL) to predict classical biomarkers, immunotherapy-associated gene signatures, and prognosis-associated subtypes directly from hematoxylin and eosin stained histopathology images. BBMIL showed the best performance among comparative algorithms on the prediction of classical biomarkers, immunotherapy related gene signatures, and subtypes.

View Article and Find Full Text PDF

Sarcopenia as a Prognostic Factor and Multimodal Interventions in Breast Cancer.

Int J Gen Med

December 2024

Department of Thyroid and Breast Surgery, Quzhou People's Hospital, Quzhou, 324000, People's Republic of China.

Objective: This study aims to demonstrate the impact of sarcopenia on the prognosis of early breast cancer and its role in early multimodal intervention.

Methods: The clinical data of patients (n=285) subjected to chemotherapy for early-stage breast cancer diagnosed pathologically between January 1, 2016, and December 31, 2020, in our hospital were retrospectively analyzed. Accordingly, the recruited subjects were divided into sarcopenia (n=85) and non-sarcopenia (n=200) groups according to CT diagnosis correlating with single-factor and multifactorial logistic regression analyses.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!